Clinician perspectives on current issues in lung cancer drug development.
Journal of Thoracic Oncology.
Times cited: 2
Erlotinib and the risk of oral cancer the erlotinib Prevention of Oral Cancer (EPOC) randomized clinical trial.
Times cited: 41
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
Clinical Cancer Research.
Times cited: 198